Hennie R. Hoogenboom

TL;DR: The first antibody of this new generation, adalimumab (Humira, a human IgG1 specific for human tumor necrosis factor (TNF)), already approved for therapy and with many more in clinical trials, these recombinant antibody technologies will provide a solid basis for the discovery of antibody-based biopharmaceuticals, diagnostics and research reagents for decades to come.

TL;DR: The results suggest that residue 6 of the heavy chain may be part of a folding nucleus, involving the first two beta-strands of Framework region 1, and may well indicate that within immunoglobulin VH domains, different family specific folding nuclei have evolved.

TL;DR: This paper showed that peptide processing rather than presentation is the rate-limiting step in their experimental setting and is much more ineffective for Melan-A than has been previously shown for other MHC class I-restricted epitopes.

TL;DR: The discovery of a GSI possessing minimal inhibition of Notch processing and maximal inhibition of APP processing to reduce 40/42 levels and structure-activity relationships in this new series and the discovery of more potent GSIs will be discussed.